Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembotm Embolic System. The Tembo ...

Arsenal Medical announced the completion of the initial cohort enrollment in the EMBO-02 clinical study of the company’s ...

Almost 800,000 total knee replacements (TKRs) are done in the U.S. every year, offering many folks a chance to reclaim total mobility. But the surgery is complex, recovery demanding, and it can pose ...

Middle meningeal artery (MMA) embolization is being utilized more frequently as adjunctive and primary treatment. It has demonstrated beneficial effects on recurrence and progression of cSDH. Here, we ...

Background The periprocedural management of antithrombotic medications in patients with chronic subdural hematoma (cSDH) after middle meningeal artery embolization (MMAE) or surgical evacuation is ...

ASC leaders are optimistic about the future, citing opportunities for growth over the next five years, including the migration of cardiology procedures to ASCs and increasing patient interest.

Q4 2024 Earnings Call Transcript February 5, 2025 Operator: Good morning, and welcome to the Boston Scientific Fourth Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is ...

According to the company, the RESORB trial is being conducted to achieve market approval for Nexsphere-F for genicular artery embolization (GAE) to treat osteoarthritis-related symptoms. The device is ...

Introduction Middle meningeal artery (MMA) embolization is becoming an increasingly established treatment option for chronic subdural hematoma (cSDH). Although several systematic reviews have ...